- Report
- September 2026
- 181 Pages
Global
From €3271EUR$3,545USD£2,762GBP
€3634EUR$3,939USD£3,069GBP
- Report
- July 2026
- 200 Pages
Global
From €7372EUR$7,990USD£6,225GBP
- Report
- July 2026
- 200 Pages
Global
From €7372EUR$7,990USD£6,225GBP
- Report
- August 2026
- 120 Pages
Global
From €4382EUR$4,750USD£3,701GBP
- Report
- August 2026
- 160 Pages
Global
From €3063EUR$3,320USD£2,587GBP
€3829EUR$4,150USD£3,233GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1153EUR$1,250USD£974GBP
- Report
- March 2022
- 324 Pages
Global
From €8765EUR$9,500USD£7,401GBP
- Drug Pipelines
- April 2025
- 90 Pages
Global
From €1845EUR$2,000USD£1,558GBP
- Report
- January 2024
- 216 Pages
United States
From €3460EUR$3,750USD£2,922GBP
The Cox Inhibitor market is a subset of the Analgesics market, which is composed of drugs used to relieve pain. Cox Inhibitors are a type of non-steroidal anti-inflammatory drug (NSAID) that work by blocking the enzyme cyclooxygenase (COX), which is responsible for the production of prostaglandins. Prostaglandins are hormones that cause inflammation and pain. By blocking the production of prostaglandins, Cox Inhibitors reduce inflammation and pain.
Cox Inhibitors are used to treat a variety of conditions, including arthritis, headaches, muscle pain, and menstrual cramps. They are available in both over-the-counter and prescription forms. Common over-the-counter Cox Inhibitors include ibuprofen, naproxen, and aspirin. Prescription Cox Inhibitors include celecoxib, etoricoxib, and meloxicam.
Some companies in the Cox Inhibitor market include Pfizer, Merck, Novartis, and Bayer. Show Less Read more